Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

To explore guidelines on the use of MRI and PET/CT monitoring primary tumor response to neoadjuvant chemotherapy (NAC), taking breast cancer subtype into account.In this prospective cohort study, 188 women were included with stages II and III breast cancer. MRI and 18F-FDG-PET/CT were acquired befor...

Full description

Bibliographic Details
Main Authors:	Alexander M Th Schmitz, Suzana C Teixeira, Kenneth E Pengel, Claudette E Loo, Wouter V Vogel, Jelle Wesseling, Emiel J Th Rutgers, Renato A Valdés Olmos, Gabe S Sonke, Sjoerd Rodenhuis, Marie Jeanne T F D Vrancken Peeters, Kenneth G A Gilhuijs
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5439668?pdf=render

Similar Items

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
by: Mette S. van Ramshorst, et al.
Published: (2017-05-01)

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
by: Anna van der Voort, et al.
Published: (2022-10-01)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
by: Max A.A. Ragusi, et al.
Published: (2021-12-01)

Agreement on indication for systemic therapy between biopsied tissue and surgical excision specimens in breast cancer patients.
by: Alexander M Th Schmitz, et al.
Published: (2014-01-01)

[18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy
by: Ariane A. van Loevezijn, et al.
Published: (2021-08-01)

Survival and prognostic factors in oligometastatic breast cancer
by: Annemiek van Ommen-Nijhof, et al.
Published: (2023-02-01)

Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
by: Josefien P. van Olmen, et al.
Published: (2024-06-01)

Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes.
by: Jorma J de Ronde, et al.
Published: (2014-01-01)

Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
by: Sjoerd G Elias, et al.
Published: (2022-09-01)

Neoadjuvant chemotherapy. How to work together – the coordination of the multidisciplinary breast team: a logistical challenge
by: E. Rutgers
Published: (2021-04-01)

Prediction of Non-Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients with <sup>18</sup>F-FDG PET Radiomics Based Machine Learning Classification
by: Roelof J. Beukinga, et al.
Published: (2022-04-01)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
by: Sonja Vliek, et al.
Published: (2023-09-01)

Efficacy Of 18FDG-PET/CT In Predicting Response After Neoadjuvant Chemoradiation In Rectal Cancer
by: Narendra Pandit, et al.
Published: (2023-08-01)

MRI VS. FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer
by: Peng Fei Gao, et al.
Published: (2023-01-01)

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study)
by: Abrahim Al-Mamgani, et al.
Published: (2023-11-01)

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
by: Anum S. Kazerouni, et al.
Published: (2023-11-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
by: Tarik Sengoz, et al.
Published: (2023-04-01)

SA 6.2 Benefits and risks of oncoplastic breast-conserving surgery
by: M.-J. Vrancken Peeters
Published: (2023-03-01)

18F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
by: Shuohua Wang, et al.
Published: (2023-08-01)

MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
by: L. M. Janssen, et al.
Published: (2022-09-01)

Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy
by: Daan Hellingman, et al.
Published: (2019-10-01)

18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
by: Tseng, J, et al.
Published: (2004)

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
by: Clement Bailly, et al.
Published: (2017-01-01)

Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma
by: Inki Lee, et al.
Published: (2020-01-01)

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.
by: Marcelo Sobral-Leite, et al.
Published: (2017-01-01)

The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
by: Yao J, et al.
Published: (2021-10-01)

Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma
by: Vijay Mistry, et al.
Published: (2023-01-01)

Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis
by: Merle M. van Leeuwen, et al.
Published: (2023-12-01)

FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer.
by: Anne I J Arens, et al.
Published: (2016-01-01)

Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET
by: Colin Hanna, et al.
Published: (2022-05-01)

Prediction of Neoadjuvant Chemoradiotherapy Response in Rectal Cancer Patients Using Harmonized Radiomics of Multcenter <sup>18</sup>F-FDG-PET Image
by: Hye-Min Ju, et al.
Published: (2023-11-01)

Multiparametric <sup>18</sup>F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
by: Lale Umutlu, et al.
Published: (2022-03-01)

Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center <sup>18</sup>F-FDG PET Images
by: Jingyu Kim, et al.
Published: (2021-10-01)

Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19–9
by: Jeongin Yoo, et al.
Published: (2023-05-01)

Utility of 18F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non‑small cell lung cancer
by: Xiaowei Chen, et al.
Published: (2023-09-01)

Dynamic 18F‐FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer
by: Zhi‐Yong Chen, et al.
Published: (2022-09-01)

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
by: Giulia Polverari, et al.
Published: (2020-10-01)

Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?
by: Letizia Deantonio, et al.
Published: (2018-10-01)

Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
by: LU Shengnan, et al.
Published: (2019-02-01)

18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study
by: Paul M. Schneider, et al.
Published: (2018-05-01)